Ciprofloxacin
- Generic Name
- Ciprofloxacin
- Brand Names
- Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18FN3O3
- CAS Number
- 85721-33-1
- Unique Ingredient Identifier
- 5E8K9I0O4U
- Background
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
- Indication
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.
A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.
A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.
A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.
- Associated Conditions
- Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae
- Associated Therapies
- -
A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 26
- Registration Number
- NCT01929460
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles Medical Center, Los Angeles, California, United States
Antibiotic Prophylaxis in Laparoscopic Cholecystectomy
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 138
- Registration Number
- NCT01888822
- Locations
- 🇮🇹
Sapienza University of Rome- Polo Pontino, Terracina, Latina, Italy
Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 360
- Registration Number
- NCT01873690
- Locations
- 🇨🇦
St. Joseph's Hospital, St. Joseph's Health Care London, London, Ontario, Canada
Ciprofloxacin for Prevention of BK Infection
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT01789203
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Antibiotics and Hydroxychloroquine in Crohn's
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Royal Liverpool University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT01783106
- Locations
- 🇬🇧
Royal Liverpool and Broadgreen Unversity Hospitals Trust, Liverpool, Merseyside, United Kingdom
Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01772615
- Locations
- 🇩🇰
Hvidovre Hospital, Copenhagen University, Hvidovre, Copenhagen, Denmark
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 80
- Registration Number
- NCT01768663
Ciprofloxacin BioThrax Co-Administration Study
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 154
- Registration Number
- NCT01753115
- Locations
- 🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸Research Across America, Dallas, Texas, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Antibiotics for Klebsiella Liver Abscess Study
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 152
- Registration Number
- NCT01723150
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
🇸🇬Tan Tock Seng Hospital, Singapore, Singapore
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 563
- Registration Number
- NCT01659866
- Locations
- 🇺🇸
Northwestern University Department of Urology, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.